Shreehas Tambe takes charge as CEO & Managing Director of Biocon

Biocon Limited has announced the appointment of Shreehas Tambe as its Chief Executive Officer (CEO) & Managing Director (MD), effective April 1, 2026, following approvals from the Nomination & Remuneration Committee and the Board of Directors. As the first CEO of the integrated Biocon, he will lead the combined platform spanning biosimilars and generics, strengthening the company’s ability to operate at scale and compete effectively in global markets.

Shreehas Tambe joined Biocon nearly three decades ago as a management trainee and, through successive leadership roles, has played a pivotal role in scaling multiple businesses globally.

During his tenure as the CEO and Managing Director of Biocon Biologics, the company has become one of the world’s Top 5 biosimilar companies by revenue with a valuation of $5.5 billion in 2025. He led the transformational acquisition of Viatris’ biosimilars business and oversaw its rapid consolidation, creating a fully integrated, lab‑to‑patient, global biologics enterprise.

Previously, Tambe served as Chief Operating Officer and later Deputy CEO of Biocon Biologics, driving enterprise‑wide operations and global growth. Earlier at Biocon, he led the worldwide expansion of the insulins business, including the establishment of Asia’s largest integrated insulins facility in Malaysia. Tambe started his career in Research & Development and is an inventor on 61 patents, reflecting his commitment to advancing innovation.

As the first CEO & Managing Director of the combined business, he will be responsible for strengthening Biocon’s position as a global biopharma leader that is addressing the world’s most pressing healthcare needs by advancing a differentiated portfolio of biosimilars, insulins, generics and peptides (GLP‑1s).